Women with Atypical Hyperplasia at Higher Risk of Breast Cancer
Author: Mayo Clinic : Contact: firstname.lastname@example.org
Synopsis and Key Points:
Women with atypical hyperplasia of the breast have a higher risk of developing breast cancer than previously thought.
Atypical hyperplasia of the breast is a precancerous condition found in about one-tenth of the over 1 million breast biopsies with benign findings performed annually in the United States. Viewed under a microscope, atypia contains breast cells that are beginning to grow out of control (hyperplasia) and cluster into abnormal patterns (atypical). Atypia lesions are considered benign, but by its risk and appearance and genetic changes, they exhibit some of the early features of cancer.
Atypical ductal hyperplasia, abbreviated ADH, is the term used for a benign lesion of the breast that indicates an increased risk of breast cancer. The name of the entity is descriptive of the lesion; ADH is characterized by cellular proliferation (hyperplasia) within one or two breast ducts and (histomorphologic) architectural abnormalities, i.e. the cells are arranged in an abnormal or atypical way. ADH, if found on a surgical (excisional) biopsy of a mammographic abnormality, does not require any further treatment, only mammographic follow-up. If ADH is found on a core (needle) biopsy (a procedure which generally does not excise a suspicious mammographic abnormality), a surgical biopsy, i.e. a breast lumpectomy, to completely excise the abnormality and exclude breast cancer is the typical recommendation.
Data from hundreds of women with these benign lesions indicate that their absolute risk of developing breast cancer grows by over 1 percent a year. The study found that after five years, 7 percent of these women had developed the disease; after 10 years, that number had increased to 13 percent; and after 25 years, 30 percent had breast cancer.
The finding places the more than 100,000 women diagnosed each year with atypical hyperplasia - also known as atypia - into a high-risk category, where they are more likely to benefit from intense screening and use of medications to reduce risk.
"By providing better risk prediction for this group, we can tailor a woman's clinical care to her individual level of risk," says Lynn Hartmann, M.D., an oncologist at Mayo Clinic and lead author of the study. "We need to do more for this population of women who are at higher risk, such as providing the option of MRI screenings in addition to mammograms and encouraging consideration of anti-estrogen therapies that could reduce their risk of developing cancer."
Previous research has shown that women with atypia have a fourfold to fivefold increased "relative risk" - meaning that they are four to five times more likely to develop breast cancer than women who don't have these lesions. But few studies have had the patient numbers and follow-up time to report the patients' "absolute risk" - the chance that she will develop breast cancer over a certain period of time.
To clearly define this risk, the Mayo Clinic team followed 698 women with atypia who had been biopsied at Mayo Clinic between 1967 and 2001. They reviewed pathology and medical records, and used patient follow-up questionnaires to determine which women developed breast cancer and when. The researchers found that after an average follow-up of 12.5 years, 143 women had developed the disease.
Importantly, the Mayo findings were validated by researchers at Vanderbilt University using biopsies from a separate cohort of women with atypia. Both data sets revealed that at 25 years following biopsy, 25 to 30 percent of these women had developed breast cancer.
The Mayo team had previously showed that two common statistical risk prediction models (the BCRAT and the IBIS models) performed poorly in women with atypical hyperplasia, underscoring the need to provide alternative approaches for predicting risk in this population.
"Instead of relying on a statistical model, our study provides actual data of breast cancer cases that occurred in a population of women with atypia. These absolute risk data are preferable to a hypothetical model," says Amy Degnim, M.D., co-lead author and a breast surgeon at Mayo Clinic.
The researchers were able to give an even more accurate estimate of risk by incorporating information from a patient's pathology specimen. They found that as the extent of atypia in a biopsy increased, as measured by the number of separate atypia lesions or foci, so did the woman's risk of developing breast cancer. For example, at 25 years post-biopsy, 47 percent women with three or more foci of atypia in the biopsy had developed breast cancer, compared to only 24 percent of women with one focus.
Based on these results, the research team recommends that women with atypical hyperplasia be recognized as having significantly increased lifetime risk of breast cancer and thus be candidates for screening MRI. Moreover, anti-estrogen medications like tamoxifen have already been tested in clinical trials in women with atypia and shown to lower their risk of breast cancer by 50 percent or more. Yet, Dr. Degnim says, many women with atypia are not taking the medications, in part because they and their physicians have not had solid estimates of their breast cancer risk to guide them.
As a leading institution funded by the National Cancer Institute, Mayo Clinic Cancer Center conducts basic, clinical and population science research, translating discoveries into improved methods for prevention, diagnosis, prognosis and therapy. For information on cancer clinical trials, call 1-855-776-0015 (toll-free).
Mayo Clinic is a nonprofit organization committed to medical research and education, and providing expert, whole-person care to everyone who needs healing. For more information, visit www.mayoclinic.org/about-mayo-clinic or newsnetwork.mayoclinic.org
Co-authors of the paper include Richard Santen, M.D., of the University of Virginia; and William Dupont, Ph.D., of Vanderbilt University.
The research was funded by the National Institutes of Health.
- 1: Female Colorectal Cancer: Symptoms, Pregnancy Risks, Treatment : Thomas C. Weiss (2015/08/10)
- 2: Stroke and Migraine Headaches in Females : Thomas C. Weiss (2014/09/11)
- 3: Female Pelvic Examination: Understanding What is Involved : Thomas C. Weiss (2015/05/31)
- 4: Endometriosis: Signs - Symptoms - Treatment : Carol Gable (2009/02/08)
- 5: Stress Urinary Incontinence Affects 1 in 3 Women : American Urological Association Foundation (2011/05/16)
- 6: Female Health Check Up: Things Women Should Have Checked in Medical Exams : Disabled World (2013/08/21)
- 7: Bias Keeps Women with Higher Body Weight Away From the Doctor : Drexel University (2018/04/23)
• Disabled World is strictly a news and information website provided for general informational purpose only and does not constitute medical advice. Materials presented are in no way meant to be a substitute for professional medical care by a qualified practitioner, nor should they be construed as such. Any 3rd party offering or advertising on disabled-world.com does not constitute endorsement by Disabled World. Please report outdated or inaccurate information to us.